Imovax Tetano (Tetanus Toxoid, Algeldrate)

Imovax Tetano is a tetanus toxoid vaccine used to induce immunity against tetanus toxin.

• Primary immunization: provides active protection against tetanus in individuals without prior vaccination.
• Booster vaccination: restores waning antibody levels in previously immunized persons.
• Post‑exposure prophylaxis: administered with tetanus immune globulin for wound management to prevent tetanus infection.
• Travel vaccination: given to travelers to regions with high risk of tetanus injuries.

• Tetanus toxoid is an inactivated form of the tetanus neurotoxin that retains antigenic determinants but lacks neurotoxic activity. After intramuscular or subcutaneous injection, antigen‑presenting cells process the toxoid and present it to helper T cells, which stimulate B‑cell production of high‑affinity anti‑tetanus antibodies. These antibodies neutralize circulating tetanus toxin, thereby preventing the clinical manifestations of tetanus. The immune response typically develops within two weeks, providing long‑lasting protection after a complete series.

Like all vaccines, Imovax Tetano may cause local and systemic reactions, most of which are mild and transient.

Common Side Effects

• Injection site pain: mild discomfort at the site of administration.
• Redness or swelling: localized erythema or edema.
• Low‑grade fever: transient temperature rise up to 38°C.
• Headache: mild headache lasting a day or two.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rare but requires immediate medical attention.
• Neurological symptoms: extremely rare cases of Guillain‑Barré syndrome reported.
• High fever or convulsions: uncommon systemic responses.

Before administering Imovax Tetano, health‑care professionals should consider several precautionary measures to ensure safety and efficacy.

• Assess prior tetanus immunization: verify vaccination history to determine need for primary series or booster.
• Evaluate hypersensitivity: avoid use in individuals with known allergy to any vaccine component, including latex or preservatives.
• Defer in acute severe illness: postpone vaccination until the patient recovers from moderate or severe febrile illness.
• Monitor after injection: observe the recipient for at least 15 minutes for signs of an immediate allergic reaction.
• Use with caution in immunocompromised patients: immune response may be reduced, but vaccine is not contraindicated.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imovax Tetano may interact with other agents that affect the immune system or vaccine efficacy.

Major Interactions (Avoid)

• Live attenuated vaccines: concurrent administration can diminish immune response to one or both vaccines; schedule them at separate visits.
• Immunoglobulin therapy: passive antibodies can neutralize the toxoid and reduce active immunization; avoid within 3 months of vaccination.

Moderate Interactions (Monitor Closely)

• Immunosuppressive drugs (e.g., corticosteroids, chemotherapy): may lower antibody production, consider checking post‑vaccination titers.
• Antibiotics for wound care: generally do not interfere, but monitor for infection control.
• Pregnancy: limited safety data; use only if benefits outweigh potential risks and after risk assessment.